{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:50:54Z","timestamp":1791366654532,"version":"4.3.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"41","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,10,28]]},"DOI":"10.1038\/s41388-026-03971-x","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:56:52Z","timestamp":1787727412000},"page":"4420-4441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decitabine suppresses triple-negative breast cancer by disrupting DNMT1 liquid-liquid phase separation and synergizes with G9a inhibition"],"prefix":"10.1038","volume":"45","author":[{"given":"Meilin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenmei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyue","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4221","authenticated-orcid":false,"given":"Xiancai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0846-8355","authenticated-orcid":false,"given":"Xinxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"3971_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA: A Cancer J Clin"},{"key":"3971_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134\u201350.","journal-title":"Lancet"},{"key":"3971_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"3971_CR4","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;378:771\u201384.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"3971_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22674","volume":"35","author":"Z Rahman","year":"2021","unstructured":"Rahman Z, Bazaz MR, Devabattula G, Khan MA, Godugu C. Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer. J Biochem Mol Toxicol. 2021;35:e22674.","journal-title":"J Biochem Mol Toxicol"},{"key":"3971_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724\u201334.","journal-title":"N Engl J Med"},{"key":"3971_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719\u201326.","journal-title":"J Clin Oncol"},{"key":"3971_CR8","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple-negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"key":"3971_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.","journal-title":"J Hematol Oncol"},{"key":"3971_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"3971_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100729","volume":"53","author":"N Wiesel-Motiuk","year":"2020","unstructured":"Wiesel-Motiuk N, Assaraf YG. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology. Drug Resistance Updates. 2020;53:100729.","journal-title":"Drug Resistance Updates"},{"key":"3971_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16:100.","journal-title":"J Hematol Oncol"},{"key":"3971_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/ng1068","volume":"33","author":"M-F Robert","year":"2003","unstructured":"Robert M-F, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 2003;33:61\u20135.","journal-title":"Nat Genet"},{"key":"3971_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neo.2020.01.002","volume":"22","author":"J Jiao","year":"2020","unstructured":"Jiao J, Lv Z, Zhang P, Wang Y, Yuan M, Yu X, et al. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines. Neoplasia. 2020;22:142\u201353.","journal-title":"Neoplasia"},{"key":"3971_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41418-019-0389-3","volume":"27","author":"H Liu","year":"2020","unstructured":"Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y, et al. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 2020;27:966\u201383.","journal-title":"Cell Death Differ"},{"key":"3971_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.arcmed.2021.04.004","volume":"52","author":"G-H Lu","year":"2021","unstructured":"Lu G-H, Zhao H-M, Liu Z-Y, Cao Q, Shao R-D, Sun G. LncRNA SAMD12-AS1 promotes the progression of gastric cancer via DNMT1\/p53 axis. Arch Med Res. 2021;52:683\u201391.","journal-title":"Arch Med Res"},{"key":"3971_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2174\/138920209788920994","volume":"10","author":"T Mingqing","year":"2009","unstructured":"Mingqing T, William X, Qizhao W, Weidong X, Ruian X. Potential of DNMT and its epigenetic regulation for lung cancer therapy. Curr Genomics. 2009;10:336\u201352.","journal-title":"Curr Genomics"},{"key":"3971_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41375-018-0192-z","volume":"33","author":"C Vicente-Due\u00f1as","year":"2019","unstructured":"Vicente-Due\u00f1as C, Gonz\u00e1lez-Herrero I, Sehgal L, Garc\u00eda-Ram\u00edrez I, Rodr\u00edguez-Hern\u00e1ndez G, Pintado B, et al. Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia. Leukemia. 2019;33:249\u201378.","journal-title":"Leukemia"},{"key":"3971_CR19","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jhep.2021.06.025","volume":"75","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liang N, Yang T, Li Y, Li J, Huang Q, et al. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J Hepatol. 2021;75:1142\u201353.","journal-title":"J Hepatol"},{"key":"3971_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41417-018-0057-7","volume":"26","author":"Q-M Wang","year":"2019","unstructured":"Wang Q-M, Lian G-Y, Song Y, Peng Z-D, Xu S-H, Gong Y. Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3\/SHP-1 in non-Hodgkin lymphoma. Cancer Gene Ther. 2019;26:195\u2013207.","journal-title":"Cancer Gene Ther"},{"key":"3971_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105869","volume":"173","author":"J-H Wang","year":"2021","unstructured":"Wang J-H, Zeng Z, Sun J, Chen Y, Gao X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol Res. 2021;173:105869.","journal-title":"Pharmacol Res"},{"key":"3971_CR22","doi-asserted-by":"publisher","first-page":"a019521.","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harbor Perspect Biol. 2016;8:a019521.","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"3971_CR23","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1073\/pnas.1618706114","volume":"114","author":"F Casciello","year":"2017","unstructured":"Casciello F, Al-Ejeh F, Kelly G, Brennan DJ, Ngiow SF, Young A, et al. G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. Proc Natl Acad Sci. 2017;114:7077\u201382.","journal-title":"Proc Natl Acad Sci"},{"key":"3971_CR24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1172\/JCI57349","volume":"122","author":"C Dong","year":"2012","unstructured":"Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Investig. 2012;122:1469\u201386.","journal-title":"J Clin Investig"},{"key":"3971_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10549-014-3089-1","volume":"147","author":"MA Healey","year":"2014","unstructured":"Healey MA, Hu R, Beck AH, Collins LC, Schnitt SJ, Tamimi RM, et al. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses\u2019 Health Study. Breast Cancer Res Treat. 2014;147:639\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"3971_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.molonc.2012.06.002","volume":"6","author":"K Holm","year":"2012","unstructured":"Holm K, Grabau D, L\u00f6vgren K, Aradottir S, Gruvberger-Saal S, Howlin J, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012;6:494\u2013506.","journal-title":"Mol Oncol"},{"key":"3971_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10555-023-10146-7","volume":"43","author":"C Thakur","year":"2024","unstructured":"Thakur C, Qiu Y, Pawar A, Chen F. Epigenetic regulation of breast cancer metastasis. Cancer Metastasis Rev. 2024;43:597\u2013619.","journal-title":"Cancer Metastasis Rev"},{"key":"3971_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107205","volume":"204","author":"L Zhou","year":"2024","unstructured":"Zhou L, Yu C-W. Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment. Pharmacol Res. 2024;204:107205.","journal-title":"Pharmacol Res"},{"key":"3971_CR29","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1021\/pr401248f","volume":"13","author":"SW Harshman","year":"2014","unstructured":"Harshman SW, Hoover ME, Huang C, Branson OE, Chaney SB, Cheney CM, et al. Histone H1 phosphorylation in breast cancer. J Proteome Res. 2014;13:2453\u201367.","journal-title":"J Proteome Res"},{"key":"3971_CR30","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41556-021-00781-z","volume":"23","author":"Y Li","year":"2021","unstructured":"Li Y, Qiu X, Wang X, Liu H, Geck RC, Tewari AK, et al. FGFR-inhibitor-mediated dismissal of SWI\/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. Nat Cell Biol. 2021;23:1187\u201398.","journal-title":"Nat Cell Biol"},{"key":"3971_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101504","volume":"5","author":"M Bagheri","year":"2024","unstructured":"Bagheri M, Mohamed GA, Mohamed Saleem MA, Ognjenovic NB, Lu H, Kolling FW, et al. Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer. Cell Rep Med. 2024;5:101504.","journal-title":"Cell Rep Med"},{"key":"3971_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O\u2019Donnell MR, DiPersio JF. Multicenter, Phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28:556\u201361.","journal-title":"J Clin Oncol"},{"key":"3971_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3324\/haematol.2011.048231","volume":"97","author":"L Michael","year":"2012","unstructured":"Michael L, Bj\u00f6rn HR, Rainer C, Claudia S, Mathias S, Ulrich G, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393\u2013401.","journal-title":"Haematologica"},{"key":"3971_CR34","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1158\/1535-7163.MCT-19-0745","volume":"19","author":"ML Dahn","year":"2020","unstructured":"Dahn ML, Cruickshank BM, Jackson AJ, Dean C, Holloway RW, Hall SR, et al. Decitabine response in breast cancer requires efficient drug processing and is not limited by multidrug resistance. Mol Cancer Ther. 2020;19:1110\u201322.","journal-title":"Mol Cancer Ther"},{"key":"3971_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100775","volume":"13","author":"C Butler","year":"2020","unstructured":"Butler C, Sprowls S, Szalai G, Arsiwala T, Saralkar P, Straight B, et al. Hypomethylating agent azacitidine is effective in treating brain metastasis triple-negative breast cancer through regulation of DNA methylation of keratin 18 gene. Transl Oncol. 2020;13:100775.","journal-title":"Transl Oncol"},{"key":"3971_CR36","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1172\/JCI97924","volume":"128","author":"J Yu","year":"2018","unstructured":"Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Investig. 2018;128:2376\u201388.","journal-title":"J Clin Investig"},{"key":"3971_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/epi.09.44","volume":"2","author":"LA Cowan","year":"2010","unstructured":"Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics. 2010;2:71\u201386.","journal-title":"Epigenomics"},{"key":"3971_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.seminoncol.2005.07.008","volume":"32","author":"RL Momparler","year":"2005","unstructured":"Momparler RL. Epigenetic therapy of cancer with 5-Aza-2\u2032-deoxycytidine (decitabine). Semin Oncol. 2005;32:443\u201351.","journal-title":"Semin Oncol"},{"key":"3971_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PA Jones","year":"1980","unstructured":"Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85\u201393.","journal-title":"Cell"},{"key":"3971_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/cancers14010248","volume":"14","author":"W Nakajima","year":"2022","unstructured":"Nakajima W, Miyazaki K, Sakaguchi M, Asano Y, Ishibashi M, Kurita T, et al. Epigenetic priming with decitabine augments the therapeutic effect of cisplatin on triple-negative breast cancer cells through induction of proapoptotic factor NOXA. Cancers. 2022;14:248.","journal-title":"Cancers"},{"key":"3971_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","volume":"30","author":"NE Muvarak","year":"2016","unstructured":"Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents \u2013 a potential therapy for cancer. Cancer Cell. 2016;30:637\u201350.","journal-title":"Cancer Cell"},{"key":"3971_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13046-018-0988-8","volume":"37","author":"Y Su","year":"2018","unstructured":"Su Y, Hopfinger NR, Nguyen TD, Pogash TJ, Santucci-Pereira J, Russo J. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. J Exp Clin Cancer Res. 2018;37:314.","journal-title":"J Exp Clin Cancer Res"},{"key":"3971_CR43","doi-asserted-by":"publisher","first-page":"487.","DOI":"10.3389\/fimmu.2015.00487","volume":"6","author":"F Casciello","year":"2015","unstructured":"Casciello F, Windloch K, Gannon F, Lee JS. Functional role of G9a histone methyltransferase in cancer. Front Immunol. 2015;6:487.","journal-title":"Front Immunol"},{"key":"3971_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2017.05.015","volume":"67","author":"L Wei","year":"2017","unstructured":"Wei L, Chiu DK-C, Tsang FH-C, Law C-T, Cheng CL-H, Au SL-K, et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2017;67:758\u201369.","journal-title":"J Hepatol"},{"key":"3971_CR45","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","volume":"25","author":"S Kubicek","year":"2007","unstructured":"Kubicek S, O\u2019Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25:473\u201381.","journal-title":"Mol Cell"},{"key":"3971_CR46","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1158\/0008-5472.CAN-17-3953","volume":"78","author":"M Liu","year":"2018","unstructured":"Liu M, Thomas SL, DeWitt AK, Zhou W, Madaj ZB, Ohtani H, et al. Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells. Cancer Res. 2018;78:5754\u201366.","journal-title":"Cancer Res"},{"key":"3971_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/hep.30168","volume":"69","author":"M B\u00e1rcena-Varela","year":"2019","unstructured":"B\u00e1rcena-Varela M, Caruso S, Llerena S, \u00c1lvarez-Sola G, Uriarte I, Latasa MU, et al. Dual targeting of histone methyltransferase G9a and DNA methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology. 2019;69:587\u2013603.","journal-title":"Hepatology"},{"key":"3971_CR48","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202153855","volume":"23","author":"L Wu","year":"2022","unstructured":"Wu L, Pan T, Zhou M, Chen T, Wu S, Lv X, et al. CBX4 contributes to HIV-1 latency by forming phase-separated nuclear bodies and SUMOylating EZH2. EMBO Rep. 2022;23:e53855.","journal-title":"EMBO Rep"},{"key":"3971_CR49","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106632","volume":"40","author":"X Ma","year":"2021","unstructured":"Ma X, Chen T, Peng Z, Wang Z, Liu J, Yang T, et al. Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies. EMBO J. 2021;40:e106632.","journal-title":"EMBO J"},{"key":"3971_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19843-1","volume":"11","author":"A Savastano","year":"2020","unstructured":"Savastano A, Ib\u00e1\u00f1ez de Opakua A, Rankovic M, Zweckstetter M. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nat Commun. 2020;11:6041.","journal-title":"Nat Commun"},{"key":"3971_CR51","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41422-021-00530-9","volume":"31","author":"R-H Li","year":"2021","unstructured":"Li R-H, Tian T, Ge Q-W, He X-Y, Shi C-Y, Li J-H, et al. A phosphatidic acid-binding lncRNA SNHG9 facilitates LATS1 liquid\u2013liquid phase separation to promote oncogenic YAP signaling. Cell Res. 2021;31:1088\u2013105.","journal-title":"Cell Res"},{"key":"3971_CR52","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/s43018-024-00816-y","volume":"5","author":"B Lu","year":"2024","unstructured":"Lu B, Qiu R, Wei J, Wang L, Zhang Q, Li M, et al. Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer. Nat Cancer. 2024;5:1622\u201340.","journal-title":"Nat Cancer"},{"key":"3971_CR53","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","volume":"21","author":"JK Christman","year":"2002","unstructured":"Christman JK. 5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483\u201395.","journal-title":"Oncogene"},{"key":"3971_CR54","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3892\/ijo.2012.1546","volume":"41","author":"DY Shin","year":"2012","unstructured":"Shin DY, Park Y-S, Yang K, Kim G-Y, Kim W-J, Han MH, et al. Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol. 2012;41:910\u20138.","journal-title":"Int J Oncol"},{"key":"3971_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2017.09.015","volume":"62","author":"Y Huang","year":"2017","unstructured":"Huang Y, Zou Y, Lin L, Ma X, Huang X. Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells. Leuk Res. 2017;62:34\u20139.","journal-title":"Leuk Res"},{"key":"3971_CR56","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1158\/1078-0432.CCR-13-1453","volume":"20","author":"TE Fandy","year":"2014","unstructured":"Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS-generating enzymes. Clin Cancer Res. 2014;20:1249\u201358.","journal-title":"Clin Cancer Res"},{"key":"3971_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s41236-020-0010-1","volume":"4","author":"Y Shen","year":"2020","unstructured":"Shen Y, Schmidt BUS, Kubitschke H, Morawetz EW, Wolf B, K\u00e4s JA, et al. Detecting heterogeneity in and between breast cancer cell lines. Cancer Convergence. 2020;4:1.","journal-title":"Cancer Convergence"},{"key":"3971_CR58","doi-asserted-by":"publisher","first-page":"68803","DOI":"10.18632\/oncotarget.11931","volume":"7","author":"A Amaro","year":"2016","unstructured":"Amaro A, Angelini G, Mirisola V, Esposito AI, Reverberi D, Matis S, et al. A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity in vivo. Oncotarget. 2016;7:68803\u201320.","journal-title":"Oncotarget"},{"key":"3971_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4408","volume":"7","author":"J Berthelet","year":"2021","unstructured":"Berthelet J, Wimmer VC, Whitfield HJ, Serrano A, Boudier T, Mangiola S, et al. The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile. Sci Adv. 2021;7:eabf4408.","journal-title":"Sci Adv"},{"key":"3971_CR60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/curroncol32020088","volume":"32","author":"DJ Kim","year":"2025","unstructured":"Kim DJ. The role of the DNA methyltransferase family and the therapeutic potential of DNMT inhibitors in tumor treatment. Curr Oncol. 2025;32:88.","journal-title":"Curr Oncol"},{"key":"3971_CR61","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/hmg\/ddx057","volume":"26","author":"M Smets","year":"2017","unstructured":"Smets M, Link S, Wolf P, Schneider K, Solis V, Ryan J, et al. DNMT1 mutations found in HSANIE patients affect interaction with UHRF1 and neuronal differentiation. Hum Mol Genet. 2017;26:1522\u201334.","journal-title":"Hum Mol Genet"},{"key":"3971_CR62","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41392-021-00678-1","volume":"6","author":"B Wang","year":"2021","unstructured":"Wang B, Zhang L, Dai T, Qin Z, Lu H, Zhang L, et al. Liquid\u2013liquid phase separation in human health and diseases. Signal Transduct Target Ther. 2021;6:290.","journal-title":"Signal Transduct Target Ther"},{"key":"3971_CR63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2018.12.035","volume":"176","author":"S Alberti","year":"2019","unstructured":"Alberti S, Gladfelter A, Mittag T. Considerations and challenges in studying liquid-liquid phase separation and biomolecular condensates. Cell. 2019;176:419\u201334.","journal-title":"Cell"},{"key":"3971_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02456-2","volume":"22","author":"M Shi","year":"2021","unstructured":"Shi M, You K, Chen T, Hou C, Liang Z, Liu M, et al. Quantifying the phase separation property of chromatin-associated proteins under physiological conditions using an anti-1,6-hexanediol index. Genome Biol. 2021;22:229.","journal-title":"Genome Biol"},{"key":"3971_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35430-y","volume":"13","author":"F Muzzopappa","year":"2022","unstructured":"Muzzopappa F, Hummert J, Anfossi M, Tashev SA, Herten D-P, Erdel F. Detecting and quantifying liquid\u2013liquid phase separation in living cells by model-free calibrated half-bleaching. Nat Commun. 2022;13:7787.","journal-title":"Nat Commun"},{"key":"3971_CR66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/71750","volume":"24","author":"F Fuks","year":"2000","unstructured":"Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 2000;24:88\u201391.","journal-title":"Nat Genet"},{"key":"3971_CR67","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1101\/gad.1463706","volume":"20","author":"P-O Est\u00e8ve","year":"2006","unstructured":"Est\u00e8ve P-O, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev. 2006;20:3089\u2013103.","journal-title":"Genes Dev"},{"key":"3971_CR68","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"W-X Xu","year":"2024","unstructured":"Xu W-X, Qu Q, Zhuang H-H, Teng X-Q, Wei Y-W, Luo J, et al. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers. Int J Biol Sci. 2024;20:1652\u201368.","journal-title":"Int J Biol Sci"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03971-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:02:43Z","timestamp":1791363763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03971-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":68,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026,10,28]]}},"alternative-id":["3971"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03971-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The Animal Ethics Committees of Guangzhou Medical University Animal Center and Guangzhou National Laboratory Animal Center approved the mouse experiments in this study (Approval Number: 20240675 and GZLAB-AUCP-2023-03-A05).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}